A Phase II Study of Daratumumab, Clarithromycin, Pomalidomide And Dexamethasone (D-ClaPd) In Multiple Myeloma Patients Previously Exposed to Daratumumab

PHASE2Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 28, 2021

Primary Completion Date

December 28, 2025

Study Completion Date

December 28, 2027

Conditions

Multiple MyelomaRefractory Multiple MyelomaRelapse Multiple Myeloma

Interventions

DRUG

Daratumumab SC

Given as 1800mg via injection

DRUG

Clarithromycin

Given as 500mg oral capsule

DRUG

Pomalidomide

Given as 4mg oral capsule

DRUG

Dexamethasone

Given as 20mg IV and 20mg or 40mg oral tablets

Trial Locations (1)

Weill Cornell Medicine - Multiple Myeloma Center, New York

All Listed Sponsors

collaborator

Janssen Scientific Affairs, LLC

INDUSTRY

lead

Weill Medical College of Cornell University

OTHER